



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313 on December 24, 2003.

SUPPLEMENTAL AMENDMENT UNDER  
37 CFR §1.111  
Examining Group 1631  
Patent Application  
Docket No. G-142US05REG  
Serial No. 09/978,418

*Frank C. Eisenschenk*

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Carolyn L. Smith  
Art Unit : 1631  
Applicants : Stephane Bejanin, Hiroaki Tanaka  
Serial No. : 09/978,418  
Filed : October 15, 2001  
Conf. No. : 7350  
For : Cytogram Polypeptides and Uses Thereof

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

SUPPLEMENTAL AMENDMENT UNDER 37 CFR §1.111

Sir:

In a Communication dated November 25, 2003, the Office Action indicates that Applicants' Amendment filed on September 15, 2003 in the above-referenced patent application is non-responsive to the previous Office Action. Specifically, the Office Action indicates that the application fails to comply with the requirements of 37 CFR 1.821 through 1.825 because it lacks SEQ ID NOs. cited along with each sequence in the specification.

By this Supplemental Amendment, Applicants have amended the subject specification to include a SEQ ID NO. for the sequences not previously identified throughout the application. In addition, a Submission of Sequence Listing Under §1.821, including a replacement sequence listing on paper and a computer readable format, is attached. Accordingly, reconsideration and withdrawal of the objection is respectfully requested.